Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Pavia, Italy : Ferrata Storti Foundation
      Original Publication: Pavia [etc.]
    • Subject Terms:
      Hemophilia A*/drug therapy ; Hemophilia A*/pathology ; Antibodies, Bispecific*/pharmacology ; Antibodies, Monoclonal, Humanized*/pharmacology ; Antibodies, Monoclonal, Humanized*/therapeutic use ; Factor VIII*/metabolism ; Fibrin*/metabolism ; Blood Coagulation*/drug effects; Animals ; Mice ; Humans ; Disease Models, Animal
    • Abstract:
      Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of thrombin substrates. Such differences may potentially result in clots with different structural and physical properties. A starting observation of incomplete wound closure in a patient on emicizumab prophylaxis led us to employ a relevant mouse model in which we noticed that emicizumab-induced clots appeared less stable compared to FVIII-induced clots. We therefore analyzed fibrin formation in vitro and in vivo. In vitro fibrin formation was faster and more abundant in the presence of emicizumab than in the presence of rFVIII/rFVIIIFc. Furthermore, the time-interval between the initiation of fibrin formation and factor XIII activation was twice as long for emicizumab than as for rFVIII/rFVIIIFc. Scanning electron microscopy and immunofluorescent spinning-disk confocal microscopy of in vivo-generated clots confirmed increased fibrin formation in the presence of emicizumab. Unexpectedly, we also detected a different morphology between rFVIII/rFVIIIFcand emicizumab-induced clots. Contrary to the regular fibrin mesh obtained with rFVIII/rFVIIIFc, fibrin fibers appeared to be fused into large patches upon emicizumab treatment. Moreover, fewer red blood cells were detected in regions in which these fibrin patches were present. The presence of highly dense fibrin structures associated with a diffuse fiber structure in emicizumab-induced clots was also observed when using super-resolution imaging. We hypothesize that the modified kinetics of thrombin, fibrin and factor XIIIa generation contribute to differences in structural and physical properties between clots formed in the presence of FVIII or emicizumab.
    • Accession Number:
      7NL2E3F6K3 (emicizumab)
      0 (Antibodies, Bispecific)
      0 (Antibodies, Monoclonal, Humanized)
      9001-27-8 (Factor VIII)
      9001-31-4 (Fibrin)
    • Publication Date:
      Date Created: 20231207 Date Completed: 20240604 Latest Revision: 20240816
    • Publication Date:
      20240817
    • Accession Number:
      PMC11141652
    • Accession Number:
      10.3324/haematol.2023.284142
    • Accession Number:
      38058210